In a study on the effectiveness of the cholesterol management drug Vytorin, researchers found that the drug was not effective on patients with a heart valve problem.Forbes: Vytorin Fails to Meet Main Goal of Heart Study (July 21, 2008)
The SEAS
The study, called a Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study, followed 1,873 patients with an aortic stenosis for four years. Two percent of individuals over the age of 65 reportedly have aortic stenosis. The study failed to show any slowing in aortic valve disease, but did show a higher rate of cancer among those who took the drug. Researchers attributed the elevated cancer incidence to chance.Forbes: Vytorin Fails to Meet Main Goal of Heart Study (July 21, 2008)
References
Fast Facts
-
Manufacturer
-
Fact:
Vytorin is a combination of the drugs ezetimibe and simvastatinOfficial Site: Vytorin
-
Study
-
Fact:
Ezetimibe sold under brand name ZetiaOfficial Site: Vytorin
-
Fact:
Ezetimibe controls amount of cholesterol absorbed by bodyVytorin: Two Sources of Cholesterol
-
Fact:
Simavastatin sold under brand name ZocorOfficial Site: Vytorin
-
Fact:
Simavastatin controls amount of cholesterol body makesVytorin: Two Sources of Cholesterol
-
Fact:
Sold only by prescriptionOfficial Site: Vytorin
-
Fact:
Study found no difference in rates of heart disease between those who took Vytorin and those who took placeboForbes: Vytorin Fails to Meet Main Goal of Heart Study (July 21, 2008)
-
Fact:
-
Fact:
